Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
Loading...
Authors
Corrigan, Kate
Haran, Maeve
McCandliss, Conor
McManus, Roisin
Cleary, Shannon
Trant, Rebecca
Kelly, Yazeed
Ledden, Kathryn
Rush, Gavin
O'Keane, Veronica
Issue Date
2021-06-15
Type
Journal Article
Language
en
Keywords
Attitudes , Hallucinogens , Lysergic acid diethylamide , Psilocybin , Psilocybin therapy , Psychedelics , Psychiatry
Alternative Title
Abstract
Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes.
To explore mental health service user attitudes to psychedelics and psilocybin therapy.
A questionnaire capturing demographics, diagnoses, previous psychedelic and other drug use, and attitudes to psychedelics and psilocybin therapy was distributed to mental health service users.
Ninety-nine participants completed the survey (52% female, mean age 42 years). The majority (72%) supported further research, with 59% supporting psilocybin as a medical treatment. A total of 27% previously used recreational psilocybin, with a male preponderance (p = 0.01). Younger age groups, those with previous psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin. A total of 55% of the total sample would accept as a treatment if doctor recommended, whereas 20% would not. Fewer people with depression/anxiety had used recreational psychedelics (p = 0.03) but were more likely to support government funded studies (p = 0.02). A minority (5%) of people with conditions (psychosis and bipolar disorder) that could be exacerbated by psilocybin thought it would be useful for them. One fifth of the total sample viewed psychedelics as addictive and unsafe even under medical supervision. Concerns included fear of adverse effects, lack of knowledge, insufficient research, illegality, and relapse if medications were discontinued.
The majority supported further research into psilocybin therapy. Younger people, those with previous recreational psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin therapy.
To explore mental health service user attitudes to psychedelics and psilocybin therapy.
A questionnaire capturing demographics, diagnoses, previous psychedelic and other drug use, and attitudes to psychedelics and psilocybin therapy was distributed to mental health service users.
Ninety-nine participants completed the survey (52% female, mean age 42 years). The majority (72%) supported further research, with 59% supporting psilocybin as a medical treatment. A total of 27% previously used recreational psilocybin, with a male preponderance (p = 0.01). Younger age groups, those with previous psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin. A total of 55% of the total sample would accept as a treatment if doctor recommended, whereas 20% would not. Fewer people with depression/anxiety had used recreational psychedelics (p = 0.03) but were more likely to support government funded studies (p = 0.02). A minority (5%) of people with conditions (psychosis and bipolar disorder) that could be exacerbated by psilocybin thought it would be useful for them. One fifth of the total sample viewed psychedelics as addictive and unsafe even under medical supervision. Concerns included fear of adverse effects, lack of knowledge, insufficient research, illegality, and relapse if medications were discontinued.
The majority supported further research into psilocybin therapy. Younger people, those with previous recreational psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin therapy.
Description
Citation
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O'Keane, V., & Kelly, J. R. (2022). Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Irish journal of medical science, 191(3), 1385–1397. https://doi.org/10.1007/s11845-021-02668-2
Publisher
License
© 2021. The Author(s).
Journal
Irish journal of medical science
Volume
191
Issue
3
PubMed ID
DOI
10.1007/s11845-021-02668-2
10.1001/jamapsychiatry.2020.2171
10.1021/acsptsci.0c00194
10.1001/jamapsychiatry.2020.3285
10.1056/NEJMoa2032994
10.1016/s2215-0366(16)30065-7
10.1007/s00213-017-4771-x
10.1177/0269881119845793
10.1007/s11033-020-06009-x
10.1177/0269881112439253
10.1177/0269881114565144
10.4088/JCP.v67n1110
10.1007/s40519-020-01000-8
10.1007/s13311-020-00962-y
10.1124/pharmrev.120.000056
10.31234/osf.io/8vks6
10.1124/pr.115.011478
10.1016/0024-3205(84)90436-3
10.1016/j.neuron.2007.01.008
10.3389/fnins.2010.00036
10.1016/j.neuropharm.2011.01.015
10.1016/j.cell.2020.08.024
10.1177/0269881120959609
10.1016/j.cell.2021.03.043
10.1073/pnas.2022489118
10.1038/s41598-017-05407-9
10.1007/s00221-013-3579-0
10.1016/j.celrep.2018.05.022
10.1038/s41586-020-3008-z
10.1021/acsptsci.0c00065
10.1038/s41386-020-0718-8
10.1038/s41583-020-0367-2
10.1097/yco.0000000000000467
10.1038/s41598-017-13282-7
10.1016/j.neuropharm.2017.12.041
10.1016/j.biopsych.2014.04.010
10.1177/2045125316689030
10.1093/schbul/sbaa117
10.1017/ipm.2020.94
10.1177/0269881116662634
10.1016/j.cell.2020.03.020
10.1002/hpja.454
10.1111/ajad.12803
10.1016/j.drugalcdep.2020.108071
10.1016/j.drugalcdep.2021.108715
10.1556/2054.01.2017.008
10.1097/nmd.0000000000000828
10.1001/jamapsychiatry.2020.3672
10.1021/acsptsci.0c00198
10.1186/s40345-014-0020-y
10.1080/02791072.2017.1344898
10.1177/0269881120908004
10.1080/02791072.2019.1593561
10.1177/0269881119857204
10.1371/journal.pone.0211023
10.1007/s00213-018-5106-2
10.1186/s12954-019-0308-4
10.1016/j.biopsych.2019.05.019
10.1007/s00213-018-5119-x
10.1007/s00213-019-05417-7
10.1021/acsptsci.0c00192
10.1002/da.23065
10.1038/s41591-021-01336-3
10.2307/3479497
10.1371/journal.pone.0214377
10.1016/s0140-6736(07)60464-4
10.1177/0269881119841569
10.1016/j.neuropharm.2018.05.012
10.1371/journal.pone.0063972
10.1016/j.neuropharm.2017.12.040
10.1136/bmj.h2902
10.1038/nrn3530
10.1016/j.drugpo.2011.02.002
10.1001/jamapsychiatry.2020.2171
10.1021/acsptsci.0c00194
10.1001/jamapsychiatry.2020.3285
10.1056/NEJMoa2032994
10.1016/s2215-0366(16)30065-7
10.1007/s00213-017-4771-x
10.1177/0269881119845793
10.1007/s11033-020-06009-x
10.1177/0269881112439253
10.1177/0269881114565144
10.4088/JCP.v67n1110
10.1007/s40519-020-01000-8
10.1007/s13311-020-00962-y
10.1124/pharmrev.120.000056
10.31234/osf.io/8vks6
10.1124/pr.115.011478
10.1016/0024-3205(84)90436-3
10.1016/j.neuron.2007.01.008
10.3389/fnins.2010.00036
10.1016/j.neuropharm.2011.01.015
10.1016/j.cell.2020.08.024
10.1177/0269881120959609
10.1016/j.cell.2021.03.043
10.1073/pnas.2022489118
10.1038/s41598-017-05407-9
10.1007/s00221-013-3579-0
10.1016/j.celrep.2018.05.022
10.1038/s41586-020-3008-z
10.1021/acsptsci.0c00065
10.1038/s41386-020-0718-8
10.1038/s41583-020-0367-2
10.1097/yco.0000000000000467
10.1038/s41598-017-13282-7
10.1016/j.neuropharm.2017.12.041
10.1016/j.biopsych.2014.04.010
10.1177/2045125316689030
10.1093/schbul/sbaa117
10.1017/ipm.2020.94
10.1177/0269881116662634
10.1016/j.cell.2020.03.020
10.1002/hpja.454
10.1111/ajad.12803
10.1016/j.drugalcdep.2020.108071
10.1016/j.drugalcdep.2021.108715
10.1556/2054.01.2017.008
10.1097/nmd.0000000000000828
10.1001/jamapsychiatry.2020.3672
10.1021/acsptsci.0c00198
10.1186/s40345-014-0020-y
10.1080/02791072.2017.1344898
10.1177/0269881120908004
10.1080/02791072.2019.1593561
10.1177/0269881119857204
10.1371/journal.pone.0211023
10.1007/s00213-018-5106-2
10.1186/s12954-019-0308-4
10.1016/j.biopsych.2019.05.019
10.1007/s00213-018-5119-x
10.1007/s00213-019-05417-7
10.1021/acsptsci.0c00192
10.1002/da.23065
10.1038/s41591-021-01336-3
10.2307/3479497
10.1371/journal.pone.0214377
10.1016/s0140-6736(07)60464-4
10.1177/0269881119841569
10.1016/j.neuropharm.2018.05.012
10.1371/journal.pone.0063972
10.1016/j.neuropharm.2017.12.040
10.1136/bmj.h2902
10.1038/nrn3530
10.1016/j.drugpo.2011.02.002
ISSN
1863-4362